NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC

Post-LOE

neomycin sulfate, polymyxin b sulfate and bacitracin zinc

Bausch + Lomb

ANDAOPHTHALMICOINTMENT

Approved

Oct 1995

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

2/8 — Basic

NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC (neomycin sulfate, polymyxin b sulfate and bacitracin zinc) by Bausch + Lomb is clinical pharmacology a wide range of antibacterial action is provided by the overlapping spectra of neomycin, polymyxin b sulfate, and bacitracin. First approved in 1995.

Drug data last refreshed 1w ago

Mechanism of Action

CLINICAL PHARMACOLOGY A wide range of antibacterial action is provided by the overlapping spectra of neomycin, polymyxin B sulfate, and bacitracin. Neomycin is bactericidal for many gram-positive and gram-negative organisms. It is an aminoglycoside antibiotic which inhibits protein synthesis by…

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Company

Worked on NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.